What Galt Pharmaceuticals does

Galt Pharmaceuticals is a privately held, self-funded specialty pharmaceutical company founded in 2016 in Atlanta, Georgia by pharmacists Dr. Barry Patel and Dr. Wade Smith. The company develops and commercializes prescription medications that target unmet clinical needs, focusing on non-opioid musculoskeletal pain (Norgesic, Orphengesic Forte), inflammatory arthritis (Tolectin), insomnia (Doral), and oral thrush (Oravig). Its core competency is reformulating and re-commercializing proven therapies that larger companies have discontinued or de-prioritized, supported by in-house regulatory expertise across NDA, ANDA, and sANDA pathways.

The company's commercial architecture is anchored by the "Phranchise" distribution model — described as the pharmaceutical industry's first franchising concept — in which 55 U.S. territories are operated by entrepreneur-owners (Phranchisees) who employ local sales and marketing staff to engage healthcare providers, while Galt retains centralized drug research, regulatory, compliance, and supply-chain functions. A parallel network of independent partner pharmacies handles dispensing, supported by the Galt Direct Help Desk and a CloudTop Health prior-authorization workflow that produces a one-page request to prescribers. Patient access is facilitated via cash-pay pricing starting at $30, $0 copay support, and deductible-credit programs targeting uninsured and underinsured patients.

Galt generates revenue from prescription product sales across its four marketed brands plus licensing/franchise fees from Phranchisees, and pursues additional growth through an in-house business-development function that actively seeks licensing, partnership, and acquisition of marketed and development-stage medicines. Operating as part of the Galt Companies parent alongside Galt Phranchise Systems, the company is led by founders Patel (CEO) and Smith (Chairman) alongside a COO with an enterprise-systems background and a Chief Regulatory Officer, with a 4-day, 36-hour workweek as a stated cultural differentiator.

Name

Galt Pharmaceuticals

Legal name

Galt Pharmaceuticals

Website

https://galtrx.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Galt Pharmaceuticals is a private, self-funded specialty pharma founded in 2016 in Atlanta that develops and commercializes prescription medications — including Norgesic, Tolectin, Oravig, and Doral — targeting non-opioid pain, arthritis, insomnia, and oral thrush, distributed via an industry-first franchised-Phranchise model across 55 U.S. territories.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Prescription pharmaceuticals
• Non-opioid pain management
• Pharmaceutical franchise model
• Specialty drug commercialization
• Drug reformulation services

Headquarters

HQ city

Atlanta

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical product sales: Galt generates revenue primarily from the sale of prescription medications including Norgesic (orphenadrine citrate/aspirin/caffeine), Tolectin (tolmetin sodium), Doral (quazepam), and Oravig (miconazole buccal). Products are sold through a network of partner pharmacies and the Phranchise distribution system.
2. Phranchise licensing fees: Galt Phranchise Systems licenses the Phranchise model to entrepreneurs who build local pharmaceutical businesses. Franchisees gain access to Galt's product portfolio, CRM platforms, marketing support, and operational systems in exchange for licensing fees.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Galt Pharmaceuticals develops and commercializes prescription medications addressing unmet clinical needs across non-opioid pain management (Norgesic, Tolectin), insomnia (Doral), and oral thrush (Oravig). The company reformulates and re-commercializes proven therapies previously discontinued by larger pharmaceutical firms, and distributes them through a proprietary pharmaceutical franchise (Phranchise) model that places entrepreneur-owned territories in local communities alongside a network of trained independent partner pharmacies.

Product overview

Galt Pharmaceuticals is a specialty pharmaceutical company that develops and commercializes prescription medications addressing unmet clinical needs. The company's portfolio consists of four currently marketed products: Norgesic (non-opioid acute musculoskeletal pain), Tolectin (osteoarthritis and rheumatoid arthritis), Oravig (oral thrush), and Doral (insomnia). Additionally, the company has two pipeline candidates in development: GA-2601 for migraine and GA-2701 for tension headaches. Galt operates a unique pharmaceutical franchising model ('Phranchise') to distribute products through local entrepreneurs and independent pharmacies, differentiating from traditional big pharma distribution.

Differentiator

Problem solved

Functional benefit

Brands

• Norgesic: Orphenadrine Citrate 25mg, Aspirin 385mg, Caffeine 30mg Tablets for non-opioid acute musculoskeletal pain relief
• Tolectin
• Oravig
• Doral
• Galt Phranchise Systems
• Galt Direct Help Desk

Products and services

• Norgesic Orphenadrine Citrate 25 mg, Aspirin 385 mg, Caffeine 30 mg Tablets for non-opioid, non-controlled, multimodal relief of mild to moderate acute musculoskeletal pain. Marketed to physicians and prescribers as an alternative to opioid pain therapies.
• Tolectin Tolmetin Sodium 400 mg Capsules and 600 mg Tablets; NSAID-based anti-inflammatory treatment for osteoarthritis and rheumatoid arthritis. Marketed as a non-opioid alternative for arthritis-related inflammatory pain.
• Oravig Miconazole Buccal 50 mg Tablets for the treatment of oral thrush (oropharyngeal candidiasis). The first and only muco-adhesive buccal tablet formulation of miconazole approved in the United States; marketed primarily to oncology and primary care prescribers.
• Doral Quazepam 15 mg Tablets; FDA-approved sedative-hypnotic medication used for the treatment of insomnia. Marketed to prescribers and supported through Galt's PAP and partner pharmacy network.
• Galt Phranchise Systems (Pharmaceutical Franchise Licensing) The industry's first pharmaceutical franchise concept that licenses the Galt Phranchise model to healthcare entrepreneurs. Franchisees gain access to Galt's product portfolio, CRM platforms, marketing support, and operational systems in exchange for licensing fees, and operate in designated territories employing their own sales and marketing associates.

Quantifiable outcome

• 2024 was Galt's best year after eight years of operation, with record sales for Doral and Orphengesic Forte
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Four partnerships are on record, tiered core.

• Fortovia TherapeuticscoreOthers · 2 December 2020Galt Pharmaceuticals acquired Oravig (Miconazole Buccal Tablets 50mg), the first and only orally-dissolving buccal tablet for oral thrush, from Fortovia Therapeutics, effective December 2, 2020. Oravig became the third product in Galt's portfolio and fits the Phranchise distribution model.
• CloudTop HealthcoreImplementation/ SI/ Consulting PartnerGalt Pharmaceuticals contracts with CloudTop Health to streamline the Prior Authorization process. Once a case is initiated by a Galt Partner Pharmacy, the provider office receives a custom-tailored 1-page request for patient diagnosis and medical history. CloudTop handles filing the case to insurance and communication to the pharmacy, eliminating this burden from provider office staff.
• Independent Pharmacy PartnerscoreChannel Partner/ Reseller/ DistributorGalt Pharmaceuticals partners with a network of independent pharmacies that are specially trained in patient communication and insurance processing to help each patient attain the lowest possible price for their prescription. These pharmacies avoid callbacks to offices regarding product availability or price that are common with large chain pharmacies. Galt prioritizes independent pharmacies for their patient responsiveness compared to chain pharmacies.
• Galt Phranchise SystemscoreStrategic or Co-development PartnerGalt Phranchise Systems is the franchise arm of Galt Companies, the parent organization of Galt Pharmaceuticals. It enables healthcare entrepreneurs to build localized, community-driven pharmaceutical businesses under the Galt brand. Phranchisees operate in designated territories and employ their own sales and marketing associates, providing education to local healthcare providers while Galt manages drug research, regulatory approval, compliance, and supply chain.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Aytu BioPharma: A specialty pharmaceutical company focused on commercializing niche prescription products, often reformulating or acquiring deprioritized assets. Similar size and product-portfolio strategy to Galt, with comparable focus on underserved therapeutic areas and a lean commercial footprint.
• ANI Pharmaceuticals: Specialty and generic pharmaceutical company that acquires, develops, and commercializes prescription medicines, including legacy and reformulated products. Closely comparable to Galt's strategy of reviving shelved therapies and building a specialty pharma portfolio.
• Cumberland Pharmaceuticals: Specialty pharmaceutical company that acquires and commercializes FDA-approved prescription products for niche therapeutic areas. Similar focus on small sales forces commercializing differentiated products in pain, GI, and other specialties — directly comparable to Galt's positioning.
• Almatica Pharma: Specialty pharmaceutical company focused on acquiring and re-commercializing prescription products, including legacy brands that have been deprioritized by larger manufacturers. Direct strategic parallel to Galt's reformulation-and-relaunch model.
• Vertical Pharmaceuticals: Specialty pharmaceutical company that acquires and markets niche prescription products, with a track record of reviving under-promoted brands. Comparable to Galt in size, therapeutic focus, and strategy of reclaiming value from shelved therapies.
• Eagle Pharmaceuticals: Specialty pharmaceutical company developing and commercializing differentiated injectable and hospital products, often improving formulations of existing molecules. Mirrors Galt's reformulation strategy and specialty commercial model.
• Journey Medical Corporation: Specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products for dermatology and other niche therapeutic areas. Similar profile to Galt — small specialty pharma with a focused portfolio and growth-by-acquisition strategy.

Broad incumbents

• Endo International: Large specialty and generic pharmaceutical company with a diversified portfolio in pain, urology, and other specialties. Endo operates at much greater scale but competes in overlapping therapeutic areas like musculoskeletal pain, making it a relevant broad incumbent for Galt.
• Amneal Pharmaceuticals: Major generic and specialty pharmaceutical manufacturer with a broad portfolio including pain, CNS, and antifungal products. Overlaps with Galt's therapeutic areas and serves as a benchmark for how a larger specialty/generic competitor can scale reformulated products.
• Bausch Health Companies: Large diversified pharmaceutical company with specialty pharma, generics, and consumer health segments. Owns the former Vertical Pharmaceuticals franchise business, providing a relevant scale benchmark for what Galt's Phranchise model could grow into over the long term.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/galtrx
• Xx.com/galtpharma
• Facebookfacebook.com/galtpharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galt Pharmaceuticals